INVO Fertility (IVF)
Operates fertility clinics and sells INVOcell for intravaginal culture.
Something off on this page? Send us feedback.
Provides fertility-clinic care and sells INVOcell, an FDA-cleared intravaginal-culture device. Most revenue comes from U.S. clinic services, which are delivered locally and supported centrally, while the device is sold through its own clinics and third-party providers.
Combines fertility-clinic services with sales of INVOcell, an FDA-cleared device designed for fertilization and early embryo development in the patient's vaginal cavity. Its U.S. clinic network provides in vitro fertilization, intravaginal culture, intrauterine insemination, evaluation, monitoring, laboratory services and fertility preservation. Care is delivered locally while finance, human resources, legal and operational functions are supported centrally.
Operates four clinics in Wisconsin, Alabama, Georgia and Indiana, and sells the device both within that network and to third-party clinics. Patients and payors pay for clinical and laboratory work as services are performed; device sales are recognized when products ship. Growth depends on clinic acquisitions and partnerships, specialized clinical staff, and outsourced device manufacturing, sterilization and logistics. Clinic and device activity remain subject to health-care, laboratory, privacy, professional-practice and FDA requirements.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $3.7M · Total debt $3.9M · Total assets $25.8M · Shareholders' equity $16.5M
- Revenue
- $2.2M
- Operating income
- −$1.3M
- Net income
- $888.7K
No dividends on record.
| Institutions6 holders · as of Mar 31, 2026 | 10.75% | 192.1K shares | |
| Insiders1 holder · as of Jan 13, 2026 | 0.00% | 0 shares | |
| Strategic holders1 holder · as of Apr 1, 2026 | 7.53% | 134.5K shares | |
| Otherremainder | 81.72% | 1.46M shares |
1.79M company shares as of Aug 21, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
The share count has not been confirmed by a second filing; stakes use it as it stands.
A stock split fell inside the quarter, so quarter-on-quarter changes are not shown.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Glenbrook Capital ManagementStrategic | 7.53% | 134,515 | 13Gfiled Apr 1, 2026 ↗ |
Mariner, LLCInstitution | 5.60% | 100,000 | 13Fas of Mar 31, 2026 |
Armistice Capital, LLCInstitution | 4.02% | 71,866 | 13Fas of Mar 31, 2026 |
Geode Capital Management, LLCInstitution | 0.94% | 16,848 | 13Fas of Mar 31, 2026 |
UBS Group AGInstitution | 0.19% | 3,321 | 13Fas of Mar 31, 2026 |
| See all 10 → | |||
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Dec 3, 2025 | Matthew K. Szot | director | −4 | $1.52 |
- CooperCompanies
IVF laboratory supplier supporting conventional embryo-culture workflows.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| INVO Fertility | $1.00 | 0.00% | $1.8M | — | — | 0.2 | +16.7% |
| CooperCompanies | $69.25 | −0.70% | $13.60B | 59.1 | 14.7 | 3.2 | +7.9% |
| Median | 59.1 | 14.7 | 3.2 | +7.9% |